Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
July 07 2022 - 08:48AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or
15d-16
Under
the Securities Exchange Act of 1934
For
the Month of July 2022
001-36345
(Commission
File Number)
GALMED
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
16
Tiomkin St.
Tel
Aviv 6578317, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover
Form
20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by
Regulation
S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by
Regulation
S-T Rule 101(b)(7): ____
On
July 7, 2022, Galmed Pharmaceuticals Ltd. issued a press release
entitled “Galmed Reports Significant Anti-Fibrotic Effects of
Aramchol in Pulmonary and Gastrointestinal Fibrosis Models
Reinforcing the Expansion of Aramchol’s Clinical Development to
Additional Indications.” A copy of the press release is attached
hereto as Exhibit 99.1 and incorporated herein by
reference.
The
first, third and fourth paragraphs of the press release attached as
Exhibit 99.1 to this Form 6-K are incorporated by reference into
the Company’s Registration Statements on Form S-8 (Registration No.
333-206292 and 333-227441) and the Company’s Registration Statement
on Form F-3 (Registration No. 333-254766).
EXHIBIT
INDEX
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Galmed
Pharmaceuticals Ltd. |
|
|
Date:
July 7, 2022 |
By: |
/s/
Allen Baharaff |
|
|
Allen
Baharaff |
|
|
President
and Chief Executive Officer |
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Jan 2023 to Feb 2023
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Feb 2022 to Feb 2023